Prof. Dr. Silvia Spörl

Medizinische Fakultät Department of Medicine 5 – Haematology and Oncology

CXCR2 expression on neutrophil granulocytes in peripheral tumor is associated with shorter survival in oral squamous cell carcinoma (2022) Spörl S, Erber R, Gerken M, Wittenberg M, Fischer R, Taxis J, Hartmann A, et al. Conference contribution Prognostic Value of Perineural Invasion on Survival and Recurrence in Oral Squamous Cell Carcinoma (2022) Spoerl S, Spörl S, Reil S, Gerken M, Ludwig N, Taxis J, Fischer R, et al. Journal article TIGIT Expression on Intratumoral Lymphocytes Correlates with Improved Prognosis in Oral Squamous Cell Carcinoma. (2022) Eichberger J, Spörl S, Spanier G, Erber R, Taxis J, Schuderer J, Ludwig N, et al. Journal article Clinical significance of panendoscopy in initial staging of oral squamous cell carcinoma and detection of synchronous second malignancies of the upper aerodigestive tract — Insights from a retrospective population-based cohort study (2022) Spoerl S, Gerken M, Chamilos C, Spörl S, Fischer R, Vielsmeier V, Künzel J, et al. Journal article Impact of spatially heterogeneous trop‐2 expression on prognosis in oral squamous cell carcinoma (2022) Erber R, Spoerl S, Mamilos A, Krupar R, Hartmann A, Rübner M, Taxis J, et al. Journal article Head and neck melanoma: outcome and predictors in a population-based cohort study (2021) Spoerl S, Spanier G, Reiter E, Gerken M, Haferkamp S, Grosse J, Drexler K, et al. Journal article A20 as a novel prognostic factor for recurrence and patients' survival in oral squamous cell carcinoma (2021) Spörl S, Erber R, Gerken M, Fischer R, Taxis J, Meier JK, Geppert CI, et al. Conference contribution Severity of COVID-19 disease is related to hyperactivation and altered migratory capacity of T cells (2021) Spörl S, Kremer AL, Aigner M, Eisenhauer N, Koch P, Meretuk L, Loeffler P, et al. Conference contribution Successful treatment of COVID-19 with convalescent plasma in B-cell depleted patients may promote cellular immunity (2021) Kremer A, Kremer A, Willam C, Verhagen J, Achenbach S, Van Der Meiden E, Lang V, et al. Conference contribution Enasidenib in IDH-2 mutant AML patients with relapse after allogeneic stem cell transplantation (2021) Vasova I, Spörl S, Guggenberger V, Berisha M, Rech D, Behzad A, Brandt A, et al. Conference contribution